Malaria Clinical Trial
Official title:
'SCHOOL-BASED TREATMENT WITH ACT TO REDUCE TRANSMISSION' (START-IPT): Evaluation of the Community Impact of Intermittent Preventive Treatment for Malaria in Ugandan Children: a Cluster Randomised Trial
We propose to evaluate the community-level impact of intermittent preventive treatment (IPT) for malaria in schoolchildren on clinical outcomes and malaria transmission, using a cluster-randomised design in Jinja, Uganda. Dihydroartemisinin-piperaquine (DP) will be administered to schoolchildren monthly for up to six rounds of treatment during one school year. Outcomes will be measured using surveys of communities, schoolchildren, and mosquito vectors. Our proposal also includes health service research to evaluate the potential feasibility of taking the programme to scale, which will guide future research and implementation of the intervention, and help shape policies in Uganda and elsewhere in Africa.
Study objective: The primary objective of the study is to evaluate the impact of IPT for
malaria in schoolchildren using monthly DP, as compared with the current standard of care
(no IPT), on community-level indicators of malaria transmission. We will test the hypothesis
that malaria transmission, as measured by the prevalence of asexual parasitaemia and the
entomological inoculation rate (EIR), will be lower in communities surrounding the
intervention schools, than those surrounding the control schools.
Study site: The study will be conducted in Jinja district, Uganda.
Clusters: A cluster will be defined as one primary day school plus the 100 closest
households surrounding the school. The clusters will be defined prior to randomisation using
digitally enumerated maps. We plan to include approximately 84 clusters in the study, with
one school per cluster; half will be randomised to the IPT intervention, and half to
control.
Randomisation: Randomisation will be conducted by the trial statistician, who is not
directly involved in the field activities. Primary schools will be stratified by type of
ownership (public vs private). Restricted randomisation will be employed to ensure balance
on type of school and geographical location.
Study population: The intervention will be delivered to children attending participating
primary schools that are randomised to the intervention group.
The IPT intervention: IPT with dihydroartemisinin-piperaquine (DP) will be delivered to all
schools located in the intervention clusters. Treatment will be administered to
participating students monthly, for up to 6 rounds of IPT during one school year, and will
not be blinded.
Administration of DP: All enrolled students will receive DP (Duo-cotexcin, Holley Cotec
Pharmaceuticals) given once a day for 3 consecutive days. DP will be dosed according to
weight-based guidelines. Full-strength DP tablets (40/320mg) will be administered orally by
study personnel, and all treatments will be directly observed.
Evaluation procedures: Outcomes will be measured through surveys of communities,
schoolchildren, and mosquito vectors. In addition, the safety of IPT with monthly DP, and
the potential feasibility of the IPT intervention will also be assessed.
1. Community surveys. Cross-sectional surveys of community residents living in households
randomly selected from each cluster will be conducted at baseline and at the end of
intervention.The community surveys will consist of two components: (1) a household
survey questionnaire administered to heads of households, and (2) a clinical survey
including laboratory testing of all household residents. The primary outcome of the
community surveys will be parasite prevalence as measured by microscopy. In the final
community survey, we plan to enroll 105 participants per cluster (8820 total).
2. School surveys. Cross-sectional surveys of students randomly selected from each cluster
school will be conducted at baseline and at the end of intervention. The primary
outcome of the school surveys will be parasite prevalence as measured by microscopy. In
the final school survey, we plan to enroll 13 students per cluster (1092 total).
3. Entomology surveys. Mosquitos will be collected using Centers of Disease Control and
Prevention (CDC) light traps from 5 randomly selected households from 20 clusters in
each study arm (100 households per arm, 200 total), using a list randomly generated
from the enumeration database. Each house will be sampled once a month for the duration
of the study. The primary outcome of the entomology surveys will be EIR.
4. Safety monitoring. Students enrolled in the intervention will be evaluated
prospectively for serious adverse events. To assess the impact of monthly IPT with DP
on risk of cardiotoxicity, a sub-set of participants (n=189) will be selected using
convenience sampling (from the intervention arm only) to participate in cardiac
monitoring and a pharmacokinetic study.
5. Qualitative assessment. A qualitative study will run alongside the main trial, to
investigate the potential feasibility for integrating this intervention into routine
health services and school systems. We will conduct a historical review of published
and unpublished literature on programmes that have integrated health interventions into
the education sector; ethnographic observation of intervention activities; and in-depth
interviews with key stakeholders, and teachers and health workers.
Analytical plan
1. Quantitative surveys: All data will be analysed on the basis of intention-to-treat,
that is, community residents and school children taking part in the final surveys will
be classified as participating in the intervention or control according to the
randomization assignment of the cluster they were surveyed in, regardless of whether
they (or their children) received the intervention or not. The primary outcome is
prevalence of asexual parasitaemia in the community surveys. Prevalence of asexual
parasitaemia in the school surveys and EIR are secondary outcome measures. An
individual-level approach to the analysis will be used due to the large number of
clusters per arm.
For binary outcomes, generalised linear Poisson models with log link function will be
used. The effect of the intervention will be quantified by calculation of a prevalence
risk ratio. For quantitative outcomes, linear regression models will be used. The
effect of the intervention will be quantified by calculation of difference in mean
outcome. Rate ratios will be used to describe the effect of the intervention on rates.
An estimate of the coefficient of variation, k, will be provided overall and for the
community survey for each age group (as defined by the stratified sampling).
The probability of selection for the final community survey was related to the sampling
frame which was determined by the expected parasite prevalence (which varies by age) in
age categories; < 5 years, 5-15 years, > 15 years. Therefore, the age structure of the
study population is not representative of the community population as a whole. Because
we are looking at the community effect we will use inverse probability weights based on
the age population structure of all clusters as recorded by the census survey. In
practice, each individual will be assigned one of three weights, generated using the
census survey, and based on their age as recorded at the final community survey.
Population estimates of prevalence will be obtained using svy commands with the cluster
as the primary sampling unit and age-related inverse probability weights. Children
selected for the school survey were randomly selected after stratification by class.
Households selected for the entomological survey were also randomly selected. No
weighting is therefore required for the analysis of either the school or entomological
surveys.
The effect of the intervention will also be assessed using adjusted analyses. The
cluster-specific prevalence or mean from the baseline survey will be adjusted for where
available. Variables collected in the baseline community survey, which were imbalanced
between trial arms, and likely to be prognostic for outcomes will be adjusted for.
Secondary analyses will be conducted to assess whether the effect of the intervention
differs by age group or school type. The effect of the intervention for each outcome
will be examined by age group or school type and tests for interaction conducted.
2. Qualitative data: The data analysis of the field notes and in-depth interviews will
follow a bottom-up approach, identifying repeating patterns in the data. Field notes
will be coded on a daily basis using qualitative data analysis software, NVivo (QSR
International, Cambridge, MA). Transcripts will be coded line-by-line, and then later
developing themes and theoretical constructs by grouping the base coding together. A
coding template will be developed and refined. Following the coding process, themes and
theoretical constructs will be developed from both the field notes and the interview
transcripts, and the analysis will be conducted with reference to the literature and
theory regarding school-based and cross-sectoral interventions. Following this
analysis, the interpretation will take on an applied stance, to seek out specific
challenges and opportunities for methods and content of interventions to support
implementation of IPT.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
| Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
| Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
| Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
| Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
| Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
| Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
| Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
| Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
| Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
| Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
| Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
| Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
| Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
| Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
| Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
| Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
| Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
| Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
| Completed |
NCT02605720 -
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
|
Phase 3 |